Scleroderma in children: Emerging management issues

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 4, 2010, Pages 348-356

  Panda, Saumya ^a  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Juvenile localized scleroderma; juvenile systemic sclerosis; scleroderma

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTICOAGULANT AGENT; ANTIFIBROTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOSARTAN; METHOTREXATE; NICARDIPINE; PENICILLAMINE; PREDNISONE; PROSTACYCLIN; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT RELAXIN; RITUXIMAB; UNINDEXED DRUG; VASODILATOR AGENT; VITAMIN D DERIVATIVE;

ARTHRITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; MYOSITIS; PUVA; RAYNAUD PHENOMENON; SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TENOSYNOVITIS; TREATMENT INDICATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; VASOSPASM;

CHILD; DERMATOLOGY; HUMANS; PEDIATRICS; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 78049394254     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.66578     Document Type: Conference Paper

References (62)

1. Doyle JA, Connolly SM, Winkelmann RK. Cutaneous and subcutaneous inflammatory sclerosis syndromes. Arch Dermatol 1982;118:886-90.
2. Belch JJ. The clinical assessment of the scleroderma spectrum disorders. Br J Rheumatol 1993;32:353-5.
3. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;24:581-90.
4. Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am 2008;34:239-55.
5. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ. The PRES/ACR/EULAR provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007;57:203-12.
6. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood-onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult-onset disease. J Rheumatol 2006;33:1004-13.
7. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A. Systemic sclerosis in childhood: Clinical and immunological features of 153 patients in an international database. Arthritis Rheum 2006;54:3971-8.
8. Misra R, Singh G, Aggarwal P, Aggarwal A. Juvenile onset systemic sclerosis: A single center experience of 23 cases from Asia. Clin Rheumatol 2007;26:1259-62.
9. Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. Systemic and localized scleroderma in children: Current and future treatment options. Paediatr Drugs 2006;8:85-97.
10. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002;138:99-105.
11. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991;18:1496-503.
12. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, doubleblind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
13. Grassegger A, Scholer G, Hessenberger G, Walder-Hantich B, Jabkwski J, Macheiner W, et al. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial. Br J Dermatol 1988;139:639-48.
14. Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, et al. Relaxin induces an extracellular matrixdegrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996;98:2739-45.
15. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. Recombinant human relaxin in the treatment of scleroderma: A randomized, double-blind, placebocontrolled trial. Ann Intern Med 2000;132:871-9.
16. Seibold JR. Relaxins: Lessons and limitations. Curr Rheumatol Rep 2002;4:275-6.
17. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RF, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
18. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
19. Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol 2007;46:218-23.
20. Foeldvari I. Scleroderma in children. Curr Opin Rheumatol 2002;14:699-703.
21. Zulian F, Kowal-Bielecka O, Miniati I, Avouac J, Chwiesko S, Aggarwal A, et al. Preliminary agreement of the Pediatric Rheumatology European Society (PRES) on the EUSTAR/EULAR recommendations for the management of systemic sclerosis in children [abstract]. Proceedings of the 14th Pediatric Rheumatology Congress. Istanbul (Turkey), September 5-9, 2007.
22. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
23. Quartier P, Bonnet D, Fournet JC, Bodemer C, Acar P, Ouachee- Chardin M, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002;29:1767-73.
24. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9.
25. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
26. Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. J Am Acad Dermatol 2008;59:1017-30.
27. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 2004;50:1005-7.
28. Ellman MH, McDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: A pilot study. Arthritis Rheum 2000;43:S392.
29. Graves J, Nunley K, Heffernan M. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol 2007;56:e55-79.
30. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, et al. Iloprost and cisaprost for Raynaud's phenomenon in systemic sclerosis. Cochrane Database Syst Rev 1998;2:CD000953.
31. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
32. Zulian F, Corona F, Gerloni V, Falcini F, Buoncompagni A, Scarazatti M, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004;43:229-33.
33. Bigby M. The hierarchy of evidence. In: Williams H, editor. Evidence-based Dermatology, 2nd ed. Malden: Blackwell Publishing; 2008. p. 34-7.
34. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted county 1960-1993. J Rheumatol 1997;24:73-80.
35. Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger Jr TA. Incidence of systemic sclerosis in Allegheney County, Pennsylvania: A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997;40:441-5.
36. Zullian F, Athreya BH, Laxer RM, Nelson AM, Feitosa de Oliveira SK, et al. Juvenile localized scleroderma: Clinical and epidemiological features in 750 children: An international study. Rheumatology (Oxford) 2006;45:614-20.
37. Zulian F, Vallongo C, de Oliveira SK, Punaro M, Ros J, Mazur- Zielinska H, et al. Congenital localized scleroderma. J Pediatr 2006;149:248-51.
38. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995;70:1068-76.
39. Zulian F, Ruperto N. Proceedings of the II Workshop on Juvenile Scleroderma Syndrome. Padua (Italy), June 3-6, 2004, quoted in Zulian (2008).
40. Martini G, Murray KJ, Howell KJ, Harper J, Atherton D, Woo P, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 2002;41: 1178-82.
41. Wiebel L, Howell KJ, Visentin MT, Rudiger A, Denton CP, Zulian F, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum 2007;56:3489-95.
42. Zulian F, Meneghesso D, Grisan E, Vittadello F, Belloni Fortina A, Pigozzi B, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007;46:856-60.
43. Liu P, Uziel Y, Chuang S, Silverman E, Krafchik B, Laxer R, et al. Localized scleroderma: Imaging features. Pediatr Radiol 1994;24:207-9.
44. Uziel Y, Feldman BM, Krafchik BR, Yeung R, Laxer R. Methotrexate and carticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000;136:91-5.
45. Guitart J, Greenberg M, Solomon LM. Localized scleroderma. In: Clements PJ, Furst DE, editors. Systemic Sclerosis. Baltimore: Williams and Wilkins; 1996. p. 65-79.
46. Stefanaki C, Stefanaki K, Kontochristopoulos G, Antoniou C, Stratigos A, Nicolaidou E, et al. topical tacrolimus 0.1% ointment in the treatment of localized scleroderma: An open label clinical and histological study. J Dermatol 2008;35:712-8.
47. Mancuso G, Berdondini RM. Localized scleroderma: Response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005;152:180-2.
48. Cunningham BB, Landells ID, Langman C, Sailer D, Paller A. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5.
49. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphea. Br J Dermatol 2005;153:815-20.
50. Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, et al. Double-blind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000;43: 1017-23.
51. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1, 25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999;16:53-8.
52. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of lowdose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006;54:440-7.
53. De Rie MA, Bos JD. Photochemotherapy for systemic and localized scleroderma. J Am Acad Dermatol 2000;43:725-6.
54. Pasic A, Ceovic R, Lipozencic R, Husar K, Susic SM, Skerlev M, et al. Phototherapy in pediatric patients. Pediatr Dermatol 2003;20:71-7.
55. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000;43:675-8.
56. Setlow RB, Grist E, Thompson K, Woodhead AD. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A 1993;90:6666-70.
57. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphea) in children. Br J Dermatol 2006;155:1013-20.
58. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Lowdose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998;39:220-5.
59. Kesler RW, McDonald TD, Balasubramaniam M, Saulsbury FT. Linear scleroderma in children. Am J Dis Child 1981;135:738-40.
60. Moynahan EJ. Penicillamine in the treatment of morphoea and keloid in children. Postgrad Med J 1974;50:39-41.
61. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990;126:609-12.
62. Zulian F. Scleroderma in children. Pediatr Clin North Am 2005;52:521-45.